Lessons from the Testosterone Trials

Peter J. Snyder, Shalender Bhasin, Glenn R. Cunningham, Alvin M. Matsumoto, Alisa J. Stephens-Shields, Jane A. Cauley, Thomas M. Gill, Elizabeth Barrett-Connor, Ronald S. Swerdloff, Christina Wang, Kristine E. Ensrud, Cora E. Lewis, John T. Farrar, David Cella, Raymond C. Rosen, Marco Pahor, Jill P. Crandall, Mark E. Molitch, Susan M. Resnick, Matthew Budoff & 9 others Emile R. Mohler, Nanette K. Wenger, Harvey Jay Cohen, Stanley Schrier, Tony M. Keaveny, David Kopperdahl, David Lee, Denise Cifelli, Susan S. Ellenberg

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled, double-blind trials in 788 men with a mean age of 72 years to determine the efficacy of increasing the testosterone levels of older men with low testosterone. Testosterone treatment increased the median testosterone level from unequivocally low at baseline to midnormal for young men after 3 months and maintained that level until month 12. In the Sexual Function Trial, testosterone increased sexual activity, sexual desire, and erectile function. In the Physical Function Trial, testosterone did not increase the distance walked in 6 minutes in men whose walk speed was slow; however, in all TTrial participants, testosterone did increase the distance walked. In the Vitality Trial, testosterone did not increase energy but slightly improved mood and depressive symptoms. In the Cognitive Function Trial, testosterone did not improve cognitive function. In the Anemia Trial, testosterone increased hemoglobin in both men who had anemia of a known cause and in men with unexplained anemia. In the Bone Trial, testosterone increased volumetric bone mineral density and the estimated strength of the spine and hip. In the Cardiovascular Trial, testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk.

Original languageEnglish (US)
Pages (from-to)369-386
Number of pages18
JournalEndocrine Reviews
Volume39
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Testosterone
Anemia
Cognition
Prostate
Placebos
Sexual Behavior
Bone Density
Hip
Coronary Vessels
Angiography
Hemoglobins
Spine
Depression

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., ... Ellenberg, S. S. (2018). Lessons from the Testosterone Trials. Endocrine Reviews, 39(3), 369-386. https://doi.org/10.1210/er.2017-00234

Lessons from the Testosterone Trials. / Snyder, Peter J.; Bhasin, Shalender; Cunningham, Glenn R.; Matsumoto, Alvin M.; Stephens-Shields, Alisa J.; Cauley, Jane A.; Gill, Thomas M.; Barrett-Connor, Elizabeth; Swerdloff, Ronald S.; Wang, Christina; Ensrud, Kristine E.; Lewis, Cora E.; Farrar, John T.; Cella, David; Rosen, Raymond C.; Pahor, Marco; Crandall, Jill P.; Molitch, Mark E.; Resnick, Susan M.; Budoff, Matthew; Mohler, Emile R.; Wenger, Nanette K.; Cohen, Harvey Jay; Schrier, Stanley; Keaveny, Tony M.; Kopperdahl, David; Lee, David; Cifelli, Denise; Ellenberg, Susan S.

In: Endocrine Reviews, Vol. 39, No. 3, 01.06.2018, p. 369-386.

Research output: Contribution to journalReview article

Snyder, PJ, Bhasin, S, Cunningham, GR, Matsumoto, AM, Stephens-Shields, AJ, Cauley, JA, Gill, TM, Barrett-Connor, E, Swerdloff, RS, Wang, C, Ensrud, KE, Lewis, CE, Farrar, JT, Cella, D, Rosen, RC, Pahor, M, Crandall, JP, Molitch, ME, Resnick, SM, Budoff, M, Mohler, ER, Wenger, NK, Cohen, HJ, Schrier, S, Keaveny, TM, Kopperdahl, D, Lee, D, Cifelli, D & Ellenberg, SS 2018, 'Lessons from the Testosterone Trials', Endocrine Reviews, vol. 39, no. 3, pp. 369-386. https://doi.org/10.1210/er.2017-00234
Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA et al. Lessons from the Testosterone Trials. Endocrine Reviews. 2018 Jun 1;39(3):369-386. https://doi.org/10.1210/er.2017-00234
Snyder, Peter J. ; Bhasin, Shalender ; Cunningham, Glenn R. ; Matsumoto, Alvin M. ; Stephens-Shields, Alisa J. ; Cauley, Jane A. ; Gill, Thomas M. ; Barrett-Connor, Elizabeth ; Swerdloff, Ronald S. ; Wang, Christina ; Ensrud, Kristine E. ; Lewis, Cora E. ; Farrar, John T. ; Cella, David ; Rosen, Raymond C. ; Pahor, Marco ; Crandall, Jill P. ; Molitch, Mark E. ; Resnick, Susan M. ; Budoff, Matthew ; Mohler, Emile R. ; Wenger, Nanette K. ; Cohen, Harvey Jay ; Schrier, Stanley ; Keaveny, Tony M. ; Kopperdahl, David ; Lee, David ; Cifelli, Denise ; Ellenberg, Susan S. / Lessons from the Testosterone Trials. In: Endocrine Reviews. 2018 ; Vol. 39, No. 3. pp. 369-386.
@article{ebe28ed8e10d4562b9ce0d9c3ede194f,
title = "Lessons from the Testosterone Trials",
abstract = "The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled, double-blind trials in 788 men with a mean age of 72 years to determine the efficacy of increasing the testosterone levels of older men with low testosterone. Testosterone treatment increased the median testosterone level from unequivocally low at baseline to midnormal for young men after 3 months and maintained that level until month 12. In the Sexual Function Trial, testosterone increased sexual activity, sexual desire, and erectile function. In the Physical Function Trial, testosterone did not increase the distance walked in 6 minutes in men whose walk speed was slow; however, in all TTrial participants, testosterone did increase the distance walked. In the Vitality Trial, testosterone did not increase energy but slightly improved mood and depressive symptoms. In the Cognitive Function Trial, testosterone did not improve cognitive function. In the Anemia Trial, testosterone increased hemoglobin in both men who had anemia of a known cause and in men with unexplained anemia. In the Bone Trial, testosterone increased volumetric bone mineral density and the estimated strength of the spine and hip. In the Cardiovascular Trial, testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk.",
author = "Snyder, {Peter J.} and Shalender Bhasin and Cunningham, {Glenn R.} and Matsumoto, {Alvin M.} and Stephens-Shields, {Alisa J.} and Cauley, {Jane A.} and Gill, {Thomas M.} and Elizabeth Barrett-Connor and Swerdloff, {Ronald S.} and Christina Wang and Ensrud, {Kristine E.} and Lewis, {Cora E.} and Farrar, {John T.} and David Cella and Rosen, {Raymond C.} and Marco Pahor and Crandall, {Jill P.} and Molitch, {Mark E.} and Resnick, {Susan M.} and Matthew Budoff and Mohler, {Emile R.} and Wenger, {Nanette K.} and Cohen, {Harvey Jay} and Stanley Schrier and Keaveny, {Tony M.} and David Kopperdahl and David Lee and Denise Cifelli and Ellenberg, {Susan S.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1210/er.2017-00234",
language = "English (US)",
volume = "39",
pages = "369--386",
journal = "Endocrine Reviews",
issn = "0163-769X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Lessons from the Testosterone Trials

AU - Snyder, Peter J.

AU - Bhasin, Shalender

AU - Cunningham, Glenn R.

AU - Matsumoto, Alvin M.

AU - Stephens-Shields, Alisa J.

AU - Cauley, Jane A.

AU - Gill, Thomas M.

AU - Barrett-Connor, Elizabeth

AU - Swerdloff, Ronald S.

AU - Wang, Christina

AU - Ensrud, Kristine E.

AU - Lewis, Cora E.

AU - Farrar, John T.

AU - Cella, David

AU - Rosen, Raymond C.

AU - Pahor, Marco

AU - Crandall, Jill P.

AU - Molitch, Mark E.

AU - Resnick, Susan M.

AU - Budoff, Matthew

AU - Mohler, Emile R.

AU - Wenger, Nanette K.

AU - Cohen, Harvey Jay

AU - Schrier, Stanley

AU - Keaveny, Tony M.

AU - Kopperdahl, David

AU - Lee, David

AU - Cifelli, Denise

AU - Ellenberg, Susan S.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled, double-blind trials in 788 men with a mean age of 72 years to determine the efficacy of increasing the testosterone levels of older men with low testosterone. Testosterone treatment increased the median testosterone level from unequivocally low at baseline to midnormal for young men after 3 months and maintained that level until month 12. In the Sexual Function Trial, testosterone increased sexual activity, sexual desire, and erectile function. In the Physical Function Trial, testosterone did not increase the distance walked in 6 minutes in men whose walk speed was slow; however, in all TTrial participants, testosterone did increase the distance walked. In the Vitality Trial, testosterone did not increase energy but slightly improved mood and depressive symptoms. In the Cognitive Function Trial, testosterone did not improve cognitive function. In the Anemia Trial, testosterone increased hemoglobin in both men who had anemia of a known cause and in men with unexplained anemia. In the Bone Trial, testosterone increased volumetric bone mineral density and the estimated strength of the spine and hip. In the Cardiovascular Trial, testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk.

AB - The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled, double-blind trials in 788 men with a mean age of 72 years to determine the efficacy of increasing the testosterone levels of older men with low testosterone. Testosterone treatment increased the median testosterone level from unequivocally low at baseline to midnormal for young men after 3 months and maintained that level until month 12. In the Sexual Function Trial, testosterone increased sexual activity, sexual desire, and erectile function. In the Physical Function Trial, testosterone did not increase the distance walked in 6 minutes in men whose walk speed was slow; however, in all TTrial participants, testosterone did increase the distance walked. In the Vitality Trial, testosterone did not increase energy but slightly improved mood and depressive symptoms. In the Cognitive Function Trial, testosterone did not improve cognitive function. In the Anemia Trial, testosterone increased hemoglobin in both men who had anemia of a known cause and in men with unexplained anemia. In the Bone Trial, testosterone increased volumetric bone mineral density and the estimated strength of the spine and hip. In the Cardiovascular Trial, testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk.

UR - http://www.scopus.com/inward/record.url?scp=85048580070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048580070&partnerID=8YFLogxK

U2 - 10.1210/er.2017-00234

DO - 10.1210/er.2017-00234

M3 - Review article

VL - 39

SP - 369

EP - 386

JO - Endocrine Reviews

JF - Endocrine Reviews

SN - 0163-769X

IS - 3

ER -